Fritextsökning
Innehållstyper
-
Anocca raises SEK 440 million ahead of clinical cancer trial
Swedish cell therapy biotech Anocca has successfully raised SEK 440 million in a new funding round to support upcoming clinical trials in pancreatic cancer.
-
Agreement in the EU on eight years of data exclusivity for new medicines
New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the dec...
-
Large study on milk: Risky for women but not for men
The risk of ischemic heart disease (IHD) and acute myocardial infarction (MI) increased for women with milk intake levels higher than 2 glasses per day, while n...
-
Heart Monitoring in Breast Cancer – Essential or Excessive?
Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.
-
Quality Assurance for the Highest Medical Standards
Metrology Solutions for Medical Components.
-
Mikael Kubista back with new venture after turbulent exit
Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...
-
Higher throughput in less time
Do you want to automate your quality processes, shorten inspection times and increase your throughput? Gain inspiration from the experience of the medical techn...
-
Will the FDA’s new transparency policy extend to medical devices? (Part 1)
In a significant policy shift, the FDA has begun publishing Complete Response Letters (CRLs) for drug and biologic applications that were initially rejected but...
-
Tablettbehandling minskade återfall i bröstcancer med 30 procent i studie
En ny oral läkemedelskandidat från Roche minskade risken för återfall i bröstcancer med 30 procent i en klinisk studie i sen fas.
-
Framgång i fas III för Sanofis eksembehandling
Antikroppen amlitelimab visar positiva data i fas III som behandling för atopisk dermatit. Franska Sanofi planerar nu globala regulatoriska ansökningar före årets slut.
-
Björn Arvidsson: ”We need to change perspective”
If you say “life science” to a person on the street and ask them to explain what it is, you will probably get no good answer. The same question to your network ...
-
Lundabolag expanderar i Europa genom nytt avtal
Acucort expanderar genom ett avtal om kommersialisering i sex olika europeiska länder.
-
Wegovy approved in the U.S. for treatment of liver disease
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. ...
-
GSK i miljardaffär – får tillgång till matallergikandidat
GSK förvärvar det amerikanska bioteknikbolaget Rapt Therapeutics i en affär värderad till cirka 2,2 miljarder dollar.
-
An increasing number of people are falling ill with TBE – “Much more research is needed”
Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Över...
-
Novo tar försprång i kapplöpning om fetmapiller
Tidiga siffror pekar på en positiv start för Novo Nordisks Wegovy i tablettform som fått ett förstahandsövertag på den amerikanska marknaden. Samtidigt väntar r...
-
How the Foreign Office will promote Swedish life science exports
The broadness and innovative strength keep Swedish life science exports strong, but the protectionist tendencies in the world are worrying, says Camilla Melland...
-
Final assembly inspection of medical plastics
Technical paper by ZEISS Medical Industry Solutions.
-
Säker visuell nivåkontroll i krävande processmiljöer
OEM Automatic erbjuder synglas, nivåställ och siktglas från KSR Kuebler WIKA group – utvecklade för visuell nivåkontroll i applikationer med höga krav på säkerh...
-
“Don’t postpone the transition to IVDR”
Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...
-
Koleraämne prövas mot cancer i svensk studie
Kolerabakterier har inget gott rykte, men i Umeå har forskare funnit en oväntad användning för dem – som del av en potentiell framtida behandling mot cancer.
-
Framsteg i fas III för Diamyds diabetesprogram
Diamyd Medical har slutfört screeningperioden i sin pågående fas III-studie inom typ 1-diabetes – och dessutom har prövningssubstansen nu fått sitt globala, gen...
-
Positive trend for Swedish medtech exports – “We have new markets that are huge”
In 2024, Swedish exports of pharmaceuticals decreased for the first time in several years. However, the trend for medical technology looks brighter. During a se...
BREAKING